Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycosylphosphatidylinositol-anchored proteins (GPI-APs) are a diverse class of cell-surface proteins that are covalently attached to the plasma membrane via a complex glycolipid anchor [1]. This post-translational modification occurs in the endoplasmic reticulum and is essential for the stable expression and functional localization of over 150 different proteins in humans, including enzymes, receptors, and adhesion molecules [2]. GPI-APs play critical roles in signal transduction, immune regulation, and apical sorting in polarized cells [3]. Deficiencies in the GPI biosynthesis pathway, such as those caused by somatic mutations in the PIGA gene, lead to Paroxysmal Nocturnal Hemoglobinuria (PNH), where the loss of GPI-anchored complement regulators CD55 and CD59 results in chronic intravascular hemolysis [4]. Additionally, GPI-APs serve as receptors for various bacterial toxins and are involved in the pathogenesis of prion diseases [5]. Therapeutic strategies targeting this class include complement inhibitors to manage PNH symptoms and novel antifungal agents, such as manogepix, which selectively inhibit the fungal GPI biosynthesis pathway [6]. Sources: [1] Kinoshita T. (2020). Biosynthesis and biology of mammalian GPI-anchored proteins. Gene. [2] Ferguson M.A.J., et al. (2015). Glycosylphosphatidylinositol Anchors. Essentials of Glycobiology. [3] Paulick M.G., Bertozzi C.R. (2008). The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure. Biochemistry. [4] Brodsky R.A. (2014). Paroxysmal nocturnal hemoglobinuria. Blood. [5] Taylor D.R., Hooper N.M. (2006). The prion protein and lipid rafts. Molecular Membrane Biology. [6] Miyazaki M., et al. (2011). In vitro and in vivo antifungal activities of E1210, a novel GPI-biosynthesis inhibitor. Antimicrobial Agents and Chemotherapy.
Complement C5 inhibition; Complement C3 inhibition; Gwt1 protein inhibition
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycosylphosphatidylinositol-anchored proteins (GPI-anchored proteins) (GPI-APs).